Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 6/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.54 |
| ▸ | CDK2 | P24941 | 5/20 | 0.54 |
| ▸ | CDK4 | P11802 | 4/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.54 |
| ▸ | CCND1 | P24385 | 4/20 | 0.54 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.54 |
| ▸ | CCND3 | P30281 | 1/20 | 0.54 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 1/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.44 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84078 | 0.98 | CDK1 (0.56) | CDK1CCNB1CDK2CDK4CCNA2 | |
| SCHEMBL83995 | 0.93 | CDK4 (0.47) | CDK1CCNB1CDK2CDK4CCNA2 | |
| SCHEMBL14004978 | 0.86 | MAPK1 (0.57) | CDK1CCNB1CDK2CDK4CCNA2 | |
| SCHEMBL14383122 | 0.86 | CDK4 (0.59) | CDK1CCNB1CDK2CDK4CCNA2 | |
| SCHEMBL17148506 | 0.84 | MKNK1 (0.52) | CDK1CCNB1CDK2CDK4CCNA2 | |
| SCHEMBL84411 | 0.84 | CDK7 (0.50) | CDK1CCNB1CDK2CDK4CCNA2 | |
| SCHEMBL24824411 | 0.83 | CCNT1 (0.49) | CDK1CCNB1CDK2CDK4CCNA2 | |
| SCHEMBL84003 | 0.79 | IKBKB (0.49) | CDK1CCNB1CDK2CDK4CCNA2 | |
| SCHEMBL91478 | 0.78 | CTSK (0.58) | CDK1CCNB1CDK2CDK4CCNA2 | |
| SCHEMBL84374 | 0.78 | HRH4 (0.40) | CDK1CCNB1CDK2CDK4CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-7696210-B2 | Gonadotropin releasing hormone receptor antagonists | WYETH (US) | 2010-04-13 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | CDK1 53/4885CCNB1 687/4885CDK2 20/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | CDK1 55/4885CCNB1 764/4885CDK2 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.